News and Media Releases

CRIS Job Scam Alert

Year In Review 2025

ACTRIS secures GMP status, ready to provide home grown novel treatments to patients

Media Coverage: Ongoing R&D to reduce manufacturing costs of CGT treatments while ensuring quality

Singapore is pioneering CAR-T cell therapy to treat blood cancer, offering patients a 50% chance of full remission. Find out how ongoing R&D aims to make these treatments more affordable.

Leadership Transition at the Advanced Cell Therapy and Research Institute, Singapore (ACTRIS)

ACTRIS welcomes A/Prof Aloysius Ho as Executive Director and Adj A/Prof Yap Eng Soo as Chief Medical Officer from 1 March 2025.

Leadership Transition at ACTRIS

Dr Cheong Wei Yang has been appointed Chair of the ACTRIS Board Oversight Committee from 1 January 2024, succeeding Prof Chee Yam Cheng. Learn about their contributions to advancing cell therapy in Singapore.

ACTRIS Marks a New Chapter in CGT with the Launch of Its National Facility

Singapore's largest national cell and gene therapy facility has launched, boosting the country's capacity for cancer treatment and regenerative medicine. Read the full press release and view event highlights here.

Launch of a New National Consortium to Advance Clinical Research and Innovation for Singapore

Singapore's new national consortium, CRIS, unites five key health R&D initiatives to advance clinical research and build a future-ready healthcare system.

ACTRIS: A new national enabler for cell and gene therapies in Singapore

Discover how cell and gene therapies are transforming cancer treatment in Singapore. Learn about ACTRIS's role in advancing local CGT manufacturing and research.

Appointment of CEO (CRIS) and ED (SCRI)

CRIS has appointed Dr Danny Soon as its first CEO to lead Singapore's clinical research and innovation efforts. Learn about CRIS and its five business units working to advance healthcare research.